FIBROGENESIS IN CIRRHOSIS - POTENTIAL FOR THERAPEUTIC INTERVENTION

被引：18

作者：

ROJKIND, M

机构：

[1] Marion Bessin Liver Research Center, Albert Einstein College of Medicine, Bronx, NY

来源：

PHARMACOLOGY & THERAPEUTICS | 1992年 / 53卷 / 01期

关键词：

D O I：

10.1016/0163-7258(92)90045-2

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Liver cirrhosis is an end stage of several diseases that affect the liver chronically. It is characterized, among other things, by excess collagen deposition, distortion of liver architecture, tissue malfunction and hemodynamic alterations. Many of the complications of cirrhosis may result from excess matrix deposition. Therefore, prevention of collagen accumulation or removal of collagen deposits could ameliorate the disease. In this article we discuss the pathophysiology of liver fibrosis and we describe various compounds with antiinflammatory and antifibrogenic activity. We discuss their possible mechanism of action and we describe animal and clinical studies in which these compounds have been utilized.

引用

页码：81 / 104

页数：24

共 239 条

[1] 16,16-DIMETHYL PROSTAGLANDIN-E2 PREVENTS THE DEVELOPMENT OF FULMINANT-HEPATITIS AND BLOCKS THE INDUCTION OF MONOCYTE MACROPHAGE PROCOAGULANT ACTIVITY AFTER MURINE HEPATITIS-VIRUS STRAIN-3 INFECTION [J].